• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Journal Scan: Treatment of primary epilepsy in cats-how well does it work?

June 24, 2013
Jennifer L. Garcia, DVM, DACVIM

This review studied the outcome of cats treated with either phenobarbital or a combination of other antiepileptic drugs with respect to the number of seizures per year and quality of life.

Untitled Document

Why they did it

There are little data in the veterinary literature about the long-term treatment of cats with primary epilepsy. The authors review the outcome of cats treated with either phenobarbital or a combination of other antiepileptic drugs with respect to the number of seizures per year and quality of life.

What they did

The study authors reviewed the medical records of 36 cats with recurrent seizures between 2001 and 2009. Primary epilepsy was diagnosed if the results of a complete work-up, which included clinical and neurologic examinations, hematologic and serum biochemical testing, cerebrospinal fluid analysis, and intracranial magnetic resonance imaging, were normal or if the work-up was not complete but more than one year had passed since seizure onset without any interictal neurologic deficits. Inclusion in the study required follow-up information for at least one year after beginning therapy, which included seizure type, duration, severity, and frequency; treatment side effects; and quality of life. The number of seizures per year was categorized into four groups:

  • Seizure-free: excellent control
Advertisement

  • 1 to 5 seizures per year: good control

  • 6 to 10 per year: moderate control

  • > 10 seizures per year: poor control

What they found

The mean age at the time of seizure onset was 4.8 years (standard deviation ± 3.51, range six months to 11 years). Half of the included cats had seizures more than 10 times a year before therapy was initiated, 11 cats had two to five seizures/year, and seven cats had six to 10 seizures/year.

Initial treatment in all cases was phenobarbital at a mean dose of 3.19 mg/kg/day. At the time of final check-up, this dose was 6.76 mg/kg/day on average. In four cats, other drugs such as diazepam, gabapentin, or levetiracetam were added to the treatment regimen. Duration of therapy averaged 1,490 days (range 365 to 4,750). The mean phenobarbital concentration was similar between seizure-free and non-seizure-free cats (27.9 vs. 31.2 µg/ml, respectively; P = 0.624); however, the correlation between serum phenobarbital concentration and adverse effects was not evaluated. One cat was euthanized because of poor seizure control despite high doses of phenobarbital and the addition of levetiracetam or gabapentin.

There was no correlation with age, sex, or body weight and seizure control. The authors found that the sooner therapy was started after diagnosis, the more likely that a cat would become seizure-free for a year or longer, but this effect was not typically noted until the second year of therapy. Cats that achieved seizure-free status for over a year tended to remain seizure-free for years. Seizures returned, however, in cases in which therapy was discontinued, suggesting that complete remission of epilepsy in cats is rare. Among the 30% of patients that were considered poorly controlled based on the number of seizures, seizure frequency and severity was improved with treatment.

Take-home message

Cats with primary epilepsy demonstrate good-to-excellent control with phenobarbital therapy, with 40% to 50% becoming seizure-free during treatment. Cats with primary epilepsy should be treated early on to achieve the best outcome, but complete remission of the disease is rare.

Pakozdy A, Sarchahi AA, Leschnik M, et al. Treatment and long-term follow-up of cats with suspected primary epilepsy. J Feline Med Surg 2013;15:267-273.

Link to abstract: http://jfm.sagepub.com/content/15/4/267.abstract

Related Content:

NeurologyFeline Medicine
FDA approves generic drug for managing allergic dermatitis in cats
FDA approves generic drug for managing allergic dermatitis in cats
Chronic feline pain from all perspectives
Chronic feline pain from all perspectives
Q&A with a keynote: Elizabeth Colleran, DVM, DABVP (Feline)
Q&A with a keynote: Elizabeth Colleran, DVM, DABVP (Feline)

Advertisement

Latest News

To refer or to not refer

Advice panel for women interested in the veterinary field

AVMA president set to testify before Congress

New Hawaii-based pet CBD brand launches

View More Latest News
Advertisement